Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • AGIR
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events

DEINOVE is pioneering the exploration of “microbial dark matter”

By revealing the metabolic potential of rare bacteria or still classified as uncultivable, the company tackles a global health and economic challenge:
ANTIMICROBIAL RESISTANCE

Latest news

30.09.2021

DEINOVE presents its financial results and the advancement of its programs for the first half of 2021

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB)...
Corporate
22.09.2021

Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on September 13, 2021

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and...
Corporate
More press releases
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

         

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home